Cagrilintide / Semaglutide Blend (5mg / 5mg)

Research overview

Cagrilintide is a 37‑amino‑acid synthetic peptide analogue derived from human amylin. It acts as a non‑selective agonist at the pancreatic amylin receptors (AMY1, AMY2, AMY3) and the calcitonin receptor (CTR). Its structure features a Cys²–Cys⁷ disulfide bond—a conserved motif of native amylin essential for receptor binding—and an N‑terminal C18 fatty diacid modification that enables albumin binding, extending its half‑life to approximately 160 hours (6.7 days). Native amylin is a neuroendocrine hormone secreted by pancreatic β‑cells; its physiological actions include delaying gastric emptying, suppressing postprandial glucagon secretion, and promoting satiety. Semaglutide is a long‑acting GLP‑1 receptor agonist with 94% sequence homology to human GLP‑1. Its molecular design includes an Aib (α‑aminoisobutyric acid) substitution and a C18 fatty acid side chain, conferring a half‑life of roughly 168 hours (7 days). Semaglutide stimulates insulin secretion and inhibits glucagon release in a glucose‑dependent manner, while also reducing body weight via central appetite suppression. When combined, cagrilintide and semaglutide target complementary, non‑overlapping pathways: semaglutide acts through the GLP‑1 receptor to delay gastric emptying, inhibit glucagon secretion, and enhance satiety; cagrilintide independently augments satiety, slows gastric emptying, and improves leptin sensitivity, primarily via the pro‑opiomelanocortin (POMC) pathway (leading to melanocortin‑4 receptor activation). When reviewed as a combined research material, the two components should remain analytically distinct. Cagrilintide is studied through amylin and calcitonin receptor systems, while semaglutide is studied through GLP-1 receptor signaling. Literature on one component should not be treated as evidence for the blend, and the material record should preserve component identity, nominal content, lot number and supporting analytical documentation.